The Evolving Role of ctDNA-Based Minimal Residual Disease Testing in Immunotherapy for Muscle-Invasive Bladder Cancer

home / between-the-lines / the-evolving-role-of-ctdna-based-minimal-residual-disease-testing-in-immunotherapy-for-muscle-invasive-bladder-cancer

Experts discuss recent advances in circulating tumor DNA (ctDNA) testing for muscle-invasive bladder cancer (MIBC), highlighting findings from three key ESMO 2025 studies, CheckMate 274, SunRISe-4, and IMvigor011, and emphasizing the growing role of ctDNA in identifying high-risk patients and guiding more personalized treatment strategies.

Two experts are featured in this series.

EP. 1: Challenges in MIBC Management and Opportunities for ctDNA-based Testing

Joshua J. Meeks, MD, PhD, BS;Alan Tan, MD

November 12th 2025

Panelists discuss new findings on adjuvant immunotherapy for high-risk bladder cancer revealing significant insights into patient outcomes and treatment strategies.

EP. 2: Exploratory Analysis of ctDNA in MIBC from CheckMate 274

Joshua J. Meeks, MD, PhD, BS;Alan Tan, MD

November 12th 2025

Panelists explore the latest insights on CTDNA in muscle-invasive bladder cancer and its impact on immunotherapy decision-making and patient outcomes.

EP. 3: Evaluating ctDNA Biomarkers in MIBC from SunRISe-4

Joshua J. Meeks, MD, PhD, BS;Alan Tan, MD

November 18th 2025

Drs. Meeks and Tan explore the SunRISe-4 trial, highlighting its innovative combination of intravesical therapy and immunotherapy.

EP. 4: Opportunities for Guiding Neoadjuvant Treatment Decisions with ctDNA in MIBC

Joshua J. Meeks, MD, PhD, BS;Alan Tan, MD

November 18th 2025

The panelists propose a nuanced view of molecular testing, suggesting ctDNA's value lies in its positive predictive capacity for identifying advanced disease, while utDNA may offer stronger negative predictive insights.

EP. 5: Assessing ctDNA-Guided Therapy in MIBC in IMvigor011

Joshua J. Meeks, MD, PhD, BS;Alan Tan, MD

November 25th 2025

The discussion centers on the Imvigor011 trial, comparing its ctDNA-guided intervention approach to prostate cancer monitoring. Dr. Meeks and Dr. Tan explore how this prospective study could transform adjuvant therapy strategies in muscle-invasive bladder cancer (MIBC).

EP. 6: Implications for ctDNA-Guided Adjuvant Decision-Making in MIBC

Joshua J. Meeks, MD, PhD, BS;Alan Tan, MD

November 25th 2025

The panelists investigate emerging molecular testing technologies, focusing on whole genome sequencing and advanced profiling techniques.